RFK Jr. Raises Concerns About a Vaccine, But Another Nation Urgently Seeks It

In the United States, the initial hepatitis B vaccine dose is administered to newborns to offer critical protection. However, it's recently been removed from the CDC's list of recommended vaccines. Contrastingly, other nations are eager to secure it.

In an unexpected move, the CDC revised its childhood vaccination schedule on Monday, reducing the number of vaccines. The three-shot hepatitis B series, crucial for liver protection, has been particularly affected.

Robert F. Kennedy Jr., Health Secretary, has questioned the safety and effectiveness of this vaccination given at birth, notably claiming a link between an ingredient in the shot and autism, although he provided no evidence.

Kennedy criticized the U.S. for exceeding other nations in the number of vaccines it recommends for children, leading to the removal of the hepatitis B newborn vaccine. Despite this, a memo from the Department of Health and Human Services highlights that 20 affluent nations advocate for hepatitis B vaccination, either at birth or later, with only Denmark and Finland diverging from this consensus.

In the U.S., health professionals link over 1,800 annual deaths to hepatitis B.

"This is unfortunate," a liver specialist at Stanford Medicine remarks. He frequently deals with cases of liver cancer, a severe outcome of the virus. "The CDC's reputation has suffered significantly."

Health professionals warn that we might see a decline in vaccination rates among children as a result.

Ghana's Efforts to Secure the Vaccine

Different from the U.S. stance, several other countries are striving to obtain the vaccine. Ghana, in West Africa, is one of these determined nations.

In Ghana, nearly 10% of the population has chronic hepatitis B, with 10,000 new cases emerging annually in its 35 million residents. The CDC estimates 20,700 new infections each year in the U.S.

The virus brings substantial risks, including cirrhosis and liver cancer, and death rates related to complications have surged in Ghana. By 2022, 14,000 people succumbed to such conditions.

Charles Adjei, the Hepatitis Alliance of Ghana's Executive Director, explains, "The burden on patients, their families, and the health system is immense." Patients often bear the expenses of their treatments independently.

The virus has spread historically along with various conditions, affecting some global regions more intensely. The absence or delay of newborn vaccinations exacerbates its transmission.

While unprotected sex and drug use are primary U.S. transmission methods, the situation in Ghana varies. "Many wrongly assume drug use and risky sex are the only ways to contract hepatitis B," explains a local expert.

In Ghana, missing the birth-dose allows unchecked mother-to-child transmission, with infection risks falling between 10% and 90%, depending on the severity of the mother's condition.

Currently, a substantial 95% of infants born to infected mothers acquire the virus, leading to significant stigma. Without management, the virus can flare up, causing serious liver diseases.

The Role of Timely Vaccination

Preventing maternal transmission is simple: an immediate birth-dose, followed by two additional injections during childhood, provides lasting protection. This first dose is crucial in preventing transmission, showing proven effectiveness.

Rachel So, a healthcare professional, stresses that the birth-dose is key in thwarting mother-to-child transmission, safeguarding the majority of newborns. Consequently, 75% to 95% of the vaccination goals are met, with the initial dose alone offering immunity to around a quarter of infants.

Despite WHO's 2009 recommendation for global newborn vaccination, Ghana has struggled to adopt this preventive measure widely. Although there were efforts to vaccinate since 2002 with high coverage, the critical newborn vaccine remains missing.

The pentavalent vaccine presently used in Ghana, covering hepatitis B and four other diseases, is administered around one month after birth, free to citizens. Unfortunately, this delay reduces its effectiveness against transmission during birth or in the womb.

Even short delays in vaccination significantly increase infection risk.

Challenges to Implementing Vaccination Programs

Dr. Yvonne Ayerki Nartey, a Cape Coast clinician, emphasizes the need for immediate newborn vaccination, saying, "We cannot afford this gap." Research shows even a small deferral in vaccination elevates infection likelihood.

The pentavalent vaccine is beneficial, but not optimal for hepatitis B prevention, as evidenced by its limited effectiveness in studies from Sierra Leone.

Moreover, it is unsafe to administer this vaccine at birth.

Another option is a dose of concentrated hepatitis B antibodies at birth, providing temporary protection, but too costly for most Ghanaians who earn around $240 monthly.

Many mothers don't know they're carriers since testing is limited and symptoms are absent. Testing fees add another barrier despite official claims that it's free.

Ghana's economic struggles, including inflation and debt, have restricted its health budget, with one of the lowest health spending rates per capita globally.

The lack of funds has impeded the establishment of a newborn vaccination program for hepatitis B.

Adjei points out, "We haven't taken the decisive step yet; Gavi's support is essential."

Gavi, which aids lower-income countries' immunization efforts, has so far not funded the birth-dose.

This co-financing system typically requires a minimal contribution per dose from countries, with Gavi covering the balance.

Historically, the 20 cents per dose price meant countries faced full costs without Gavi backing.

Lacking Gavi's negotiating clout, the actual dose could cost patients approximately $3.50 each.

Public Advocacy for Vaccine Rollout

Efforts to secure Gavi's cooperation did not go unheard. "Our advocacy began loud and clear in 2015 to prioritize this," recalls Adjei.

A famous rapper in Ghana, Okyeame Kwame, known as the Rap Doctor, has supported the cause fervently through various platforms.

Besides musical acclaim, Okyeame Kwame has been an advocate for hepatitis B awareness, partnering with groups and participating in university awareness events.

"We work together towards a common message," Kwame states, emphasizing collective effort for their objectives, hoping to banish hepatitis B.

The impact of collective advocacy reached Gavi, which in 2018 decided to fund hepatitis B birth vaccinations by 2021, though the pandemic caused delays.

Adjei, though initially optimistic, noted a tense silence as funding efforts halted because of COVID-19 constraints.

Hope for the Future

The persistent campaign brought eventual progress in 2024 when Gavi agreed to handle part of the vaccine costs, aiding Ghana's ability to acquire it extensively.

Despite the progress announcement, the initiation of the comprehensive vaccination has not yet occurred as planned.

Adjei expresses belief that the campaign will begin in 2026, though setbacks have been frustrating.

"We faced repeated assurances without progress, even as we constantly documented the mortality rates due to preventable conditions," he says, recalling their exhaustive lobbying.

"Even amidst the ongoing struggle, we remain hopeful for conclusive success," says Kwame.

Nartey warns about the obstacles countries encounter even with existing vaccination strategies, showing that full implementation is challenging.

Adjei is concerned about Gavi's future bandwidth, as financial resources tighten. Still, he stays positive, empowered by the global community's support.

In Ghana, Nartey remains optimistic for a hepatitis B-free future, reflecting, "Knowing vaccination can reduce cancer mortality justifies all efforts."